What is the most important information I should know about Fuzeon?
• Fuzeon is a fusion inhibitor that was developed by Trimeris and Hoffmann-La Roche and is now sold by Genentech, a division of Roche. It was approved by the U.S. Food and Drug Administration (FDA) in March, 2003. Fuzeon is approved for HIV-positive people who have tried other HIV drugs in the past and are unable to keep their viral loads undetectable using drugs that are currently available. It has not yet been approved for HIV-positive people who are starting HIV drug treatment for the first time. • Fuzeon must be used in combination with other HIV drugs. • Genentech has established a patient assistance program (PAP) for people living with HIV who do not have private or public health insurance and are unable to afford Fuzeon. To learn more about the PAP for Fuzeon, call 877-757-6243. What is Fuzeon? • Fuzeon is an HIV medication. It is in a category of HIV medicines called fusion inhibitors, or more broadly, entry inhibitors. • Fuzeon binds to a protein on HIV’s surface called gp41.
